Strateos Inc. services

High throughput screening (HTS) in drug discovery is critical for drug discovery and is a widely used tool for querying small molecule chemical libraries to determine the structure-activity relationship (SAR) of molecules and helps drive the development of specific and potent bioactive drugs.

One of the challenges in drug discovery and development is miniaturization. Miniaturization is key to automating small molecule discovery, facilitating higher throughput, increasing reliability and accuracy and reducing costs for screening large compound libraries. We have a solid track record in miniaturizing challenging assays to 384- and 1536-well formats for medium to Ultra-High-Throughput Screening (uHTS), and are experts at lab automation solutions to accelerate drug discovery.

Strateos offers a wide range of the shelf assays and supports custom development of biochemical, biophysical and cellular assays using both industry-standard and innovative technologies to support drug discovery projects from hit identification to lead optimization. We also have broad experience in a variety of target classes ranging from GPCRs, kinases, ion channels, nuclear receptors, proteases and protein-protein interactions in many therapeutic areas. Our highly experienced team can also provide project strategy, design, and implementation guidance throughout the process.

Hit optimization is a critical step in drug discovery to funnel into lead optimization. Select the most promising hits and leverage H2L, and automated chemical synthesis workflows for faster experimental screening cycles, decreased duration and hands on time, reducing the overall drug discovery timeline leading to promising preclinical candidates. Rapid turnaround of assay data on new small molecule structures will enable a higher number of data driven decisions about hit optimization per unit time thereby reducing the time to progress a project into the lead optimization stage.

Hit discovery or hit identification in drug development is driven by the need to identify small molecules with desirable activity in a compound screen against a target. Our state-of-the-art fully automated robotic platform is set-up to accelerate your drug discovery process starting with robust, targeted hit identification services. Our system can efficiently run biochemical, phenotypic and cellular HTS assays in 384- or 1536-well formats.